Insider Purchase: 10% Owner at $KROS Buys 500,000 Shares
Adar1 Partners Increases Stake in Keros Therapeutics With $9.1m Purchase
Keros Therapeutics(KROS.US) 10% Shareholder Buys US$9.46 Million in Common Stock
BofA Securities Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $33
We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate
Sector Update: Health Care Stocks Retreat Late Afternoon
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS) and Illumina (ILMN)
Wedbush Maintains Keros Therapeutics(KROS.US) With Hold Rating, Maintains Target Price $15
Keros Therapeutics Up Over 14%, on Pace for Largest Percent Increase Since January 2024 -- Data Talk
Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump
PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday
Sector Update: Health Care
Keros Therapeutics Shares Are Trading Higher. The Company Announced That Its Board Has Initiated a Formal Review Process to Evaluate Strategic Alternatives to Maximize Shareholder Value.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Keros Therapeutics Board Initiates Review of Strategic Alternatives
Keros Therapeutics Shares Rise Premarket as Company Mulls Sale
Express News | Keros Therapeutics Shares up 17.7% Premarket After Co Adopts 'poison Pill' Plan
Express News | Keros Therapeutics Inc - Adopted Limited-Duration Stockholder Rights Plan
Express News | Keros Therapeutics Inc - Authorized Formation of Committee, Consisting of Independent and Disinterested Directors, to Oversee Process
Express News | Keros Therapeutics Announces Review of Strategic Alternatives